Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN58758525
ISRCTN58758525
Completed
Not Applicable

A Phase II Randomised Study of the Addition of Methotrexate 0.05 mg/kg 12 hourly for 8 doses to the Current Immunosuppressant Regimen for the Prevention of Liver Allograft Rejection.

Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)0 sites60 target enrollmentSeptember 30, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
Enrollment
60
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 30, 2005
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional

Investigators

Sponsor
Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)

Eligibility Criteria

Inclusion Criteria

  • •Not provided at time of registration

Exclusion Criteria

  • •Not provided at time of registration

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Comparison between the effectiveness of methadone & Acceptance & Commitment group combination therapy & methadone therapy in the prevention rate of relapse in people with opium abuse.Mental & behavioural disorders due to use of opioids.Mental and behavioural disorders due to use of opioids
IRCT2016062328603N1Vice chancellor for research Zanjan University of Medical Sciences30
Not yet recruiting
Not Applicable
To evaluate the efficacy of two drugs methylprednisolone and etoricoxib in laproscopic surgeryHealth Condition 1: O- Medical and Surgical
CTRI/2019/03/018041Department of anaesthesiology Jln Medical College ajmer
Active, not recruiting
Not Applicable
To evaluate the effectiveness of MetaDerm Cream in Atopic Dermatitis
CTRI/2017/06/008950Haus Bioceuticals Inc
Completed
Not Applicable
RANDOMIZED PHASE II ASSAY OF CHEMOTHERAPY WITH METOTREXATE IN HIGH DOSES ONLY OR ASSOCIATED WITH CITARABINE IN HIGH DOSE, FOLLOWED BY RADIOTHERAPY ADEQUATE TO AGE AND RESPONSE FOR IMMUNOCOMPROMISED PATIENTS WITH RECENT DIAGNOSIS OF PRIMARY LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM
PER-082-03INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,
Completed
Phase 4
A clinical trial to study the effects of two drugs, Metformin Immediate Release and Metformin Extended Release in newly diagnosed type 2 diabetes mellitus patients.Health Condition 1: E119- Type 2 diabetes mellitus without complications
CTRI/2021/04/033194Bangalore Medical College and Research Institute70